At least 30 million people worldwide live with atrial fibrillation (AF). Despite improved treatment options AF patients still suffer strokes, heart failures, and premature deaths. The German Atrial Fibrillation Network association (AFNET) and the European Heart Rhythm Association (EHRA) initiated development of a roadmap to improve the quality of AF management. An international group of experts developed a set of initiatives and recommendations aimed at improving the care for AF patients. The report of the 5th AFNET/EHRA consensus conference is published online in the EP Europace journal today.
The 5th AFNET/EHRA consensus conference was convened with the focus on “Understanding and eliminating inequalities and barriers that prevent optimal treatment of atrial fibrillation”. Professor Paulus Kirchhof, one of the conference organizers, board member of EHRA and speaker of the board of AFNET, explained:
“We arranged this meeting with the aim to set out a roadmap for a tangible improvement of atrial fibrillation management. The outcome of the conference has been condensed into a set of recommendations and research priorities in AF.”
Learning from our neighbours
Over seventy AF experts, representing an almost global community of AF professionals, participated in the conference and shared their experiences. “Given the wide global variety in healthcare structures, the different countries in the world can learn from each other and develop role models of excellent AF care. We hope that this roadmap created by specialists coming from different parts of the world will help to improve AF management in Europe and beyond.” observed Professor Gerhard Hindricks, president of EHRA.
Informed and involved patients
The experts agree that for successful AF therapy all AF patients should be involved in decisions about their care. It is imperative that the patients are well informed about AF. In order to achieve this, the authors recommend enhancing the publicly available information on AF, its complications, and the therapeutic options.
Patient focused initiatives such as the website for patients “AFib matters” (http://www.afibmatters.org) developed in 5 European languages now and released by the European Heart Rhythm Association (EHRA) were considered very helpful promoting patient engagement in the field of AF. Furthermore, patient reported outcomes should be used to capture AF-related symptoms and patients’ experiences.
Adequate management of AF patients is complex. Professor Andreas Goette, board member of AFNET, explained: “Such AF care should ensure that evidence-based therapy is offered to all AF patients.” Therefore the AFNET/EHRA roadmap recommends a more structured approach led by interdisciplinary teams and suggests the development of patient-centered care plans for all AF patients.
Improving AF treatment
Several millions of people in the world suffer from undiagnosed and therefore untreated AF, associated with high risk of strokes and death. The AFNET/EHRA roadmap recommends the establishment of widespread screening for AF in those over the age of 65, or in populations at high risk, in order to make a timely diagnosis and treatment of AF possible.
Strategies to minimize interruption of discontinuation of anticoagulant therapy need to be evaluated since anticoagulants are effective only if taken continuously.
AF ablation is an established AF treatment and hence offered in an increasing number of hospitals. The authors recommend development of standards to consistently measure the quality and success of AF ablation. Often ablation does not completely eliminate AF, and further trials are needed to identify the best rhythm control therapy in patients with recurrent AF after ablation.
Personalized AF management
Further research is required to better understand the underlying cellular and molecular mechanisms of AF. The experts suggest the evaluation of genetic factors, specific biomarkers and ECG parameters to identify different subtypes of AF in individual patients in order to develop more targeted therapies. For example, new biomarkers or ECG information can be used to refine anticoagulation risk assessment individually for patients with an intermediate or low risk of stroke. Currently it is not clear whether this group of patients will benefit from anticoagulation therapy or not.
Professor A John Camm, president-elect of EHRA and co-organizer of the 5th AFNET/EHRA consensus conference, concluded: “We believe that the suggested research activities can help to optimize AF therapy and improve the outcomes of many AF patients in the world. There is an urgent need for long-term research funding to enable the implementation of appropriate studies.”
The conference was organized and co-financed by AFNET and EHRA. Industry participants paid an attendance fee.
Kirchhof P et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network / European Heart Rhythm Association consensus conference. Europace 2015; doi:10.1093/europace/euv304
The Atrial Fibrillation Network association (AFNET) is an interdisciplinary research network comprising scientists and physicians from hospitals and practices dedicated to improving the management of atrial fibrillation through coordinated research in Germany and Europe. Its main objective is to conduct high quality investigator-initiated clinical trials and registries on a national and international level. The AFNET continues the long-term activities of the network which has been funded by the German Federal Ministry of Research and Education over a decade. Since January 2015, specific projects and infrastructures of the AFNET are funded by the German Centre for Cardiovascular Research (DZHK).
The European Heart Rhythm Association (EHRA) is a registered branch of the European Society of Cardiology (ESC). Its aim is to improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reducing sudden cardiac death. EHRA promotes science and education in the field of cardiac arrhythmias with a special focus on AF. Besides patient engagement programs EHRA organizes scientific and educational events for physicians and allied professionals. In cooperation with other associations and societies EHRA promotes the quality of care for patients with atrial fibrillation with the publication of international consensus documents.
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.
Angelika Leute PhD
Phone: +49 202 2623395
http://www.af-net.eu - Atrial Fibrillation Network association (AFNET)
http://www.escardio.org/EHRA - European Heart Rhythm Association (EHRA)
http://www.escardio.org - European Society of Cardiology (ESC)
Dr. Angelika Leute | idw - Informationsdienst Wissenschaft
ICTM Conference 2017: Production technology for turbomachine manufacturing of the future
16.11.2016 | Fraunhofer-Institut für Produktionstechnologie IPT
Innovation Day Laser Technology – Laser Additive Manufacturing
01.11.2016 | Laser Zentrum Hannover e.V.
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering